


Understanding the Biomanufacturing Process and the Role Played by Biofoundries

Under supervision of Maria Savino


Contributors: Pooja Mangari, Benoit Josset, Peter Braun, Lori Euler, Sebastian Blum



ACCELERATING
answers

 **BECKMAN
COULTER**
Life Sciences

BIOMANUFACTURING is the application of biological systems and processes to produce commercially valuable products. It involves leveraging biological systems—such as microorganisms, cells or enzymes—in a controlled manufacturing environment to produce a range of products. These products span from pharmaceuticals and vaccines to biofuels, industrial materials, food, beverages, and beauty ingredients.



Contents



01. Introduction.....	4
Introduction to biomanufacturing	4
Key stages of the biomanufacturing process.....	5
02. Upstream Development	7
Selecting or reprogramming organisms.....	7
DBTL workflow	9
Various stages and equipment involved in the upstream biomanufacturing process	10
Efficient DNA assembly and editing.....	11
Automated microbial transformation system	12
Plating and automated colony picking.....	13
Nucleic acid extraction and cleanup solutions	14
NGS solutions	15
High-throughput strain screening solutions	17
Organism selection and optimization in microbial research	17
Flow cytometry solutions: CytoFLEX platforms.....	18
BioLector XT microbioreactor.....	19
03. Analytical Validation.....	20
Product analysis and verification	20
Strain optimization/medium and bioprocess optimization	21
Fermentation QC and viability validation assays.....	21
Alternative solutions for cell analysis and cell counting.....	22
04. Integrating Automation and Data Handling	23
Access Solutions Group.....	23
Data treatment and integrity	25
SAMI EX software in synthetic biology	26
05. Optimizing Downstream Process and Scale-Up.....	27
Challenges in scaling up	27
Mitigation strategies.....	28
06. Case Study - Biofoundry Workflow.....	29
Purpose and functionality	29
The role of lab automation in biofoundries	29
Technologies used in biofoundries.....	29
07. Conclusion.....	30
08. References	31

01 Introduction

Introduction to biomanufacturing

Biomanufacturing is the application of biological systems and processes to produce commercially valuable products. It involves leveraging biological systems—such as microorganisms, cells or enzymes—in a controlled manufacturing environment to produce a range of products. These products span from pharmaceuticals and vaccines to biofuels, industrial materials, food, beverages, and beauty ingredients.

Integrating cell-free systems and in vitro transcription/translation into biomanufacturing can enhance production efficiency and versatility by enabling faster prototyping, easier optimization, and the synthesis of difficult-to-express proteins. For instance, in vitro transcription (IVT) is commonly used in the production of mRNA vaccines, and for protein production in vitro transcription/translation (TX/TL) is applied (Klocke et al., 2018; N. M. Drzeniek et al., 2024).

While for the applied market the biomanufacturing goal is time to market and diminishing cost, for drug development, the main goal is effective therapeutics. Nevertheless, both domains need to apply similar research processes of bioengineering and organism selection. In this article we will focus on the non pharmaceutical processes, that try to develop sustainable processes that minimize environmental impact.

This includes creating eco-friendly biofuels, improving agricultural practices, applying the “farm to fork strategy,”¹ and reducing reliance on non-renewable resources.


The biomanufacturing process involves several key stages (Sadiku et al., 2023).

1. The “Farm to Fork” strategy is increasingly being adopted globally to create a more sustainable and resilient food system. It recognizes the interconnectedness of all stages of food production and consumption and strives to improve the overall health and sustainability of the food supply chain.



01 Introduction

Key stages of the biomanufacturing process



Industrial companies recognize the imperative to develop sustainable processes, but the major challenge today is time. Achieving Net Zero across Scopes 1, 2, and 3² within the agreed timelines requires not only significant investments but also the rapid adaptation and development of new technologies that can accelerate both research and operational efficiency. The pressure to reduce emissions quickly, while maintaining competitiveness, has created an urgent need for solutions that can decrease time-to-market and risk of failure. As a result, industries are now seeking breakthroughs that allow for faster innovation cycles, scalable decarbonization pathways, and leaner, more adaptive supply chains (Rogelj et al., 2021).

In response to these pressing challenges and the need for rapid innovation, industries are increasingly turning toward a **confluence of advances in biological science**, often referred to as the Bio Revolution.

McKinsey defines the Bio Revolution as a transformative period in biological sciences that has the potential to significantly impact various sectors, including human health, agriculture, consumer products, and materials. This revolution is characterized by the increased ability to engineer and reprogram both human and non-human organisms, enhancing control and precision in biological processes (McKinsey Global Institute, 2020).

2. Scope 1: Direct emissions resulting from vehicles, fuel use, and/or chemical leakage; Scope 2: Indirect emissions resulting from bought electricity, cooling, heat and/or steam; Scope 3: Other indirect emissions that occur in the value chain of a company and are not already included within scope 2 (such as emissions resulting from purchased goods and services, transport, or business travel)

01 Introduction

Modern biotechnology advances span pharmaceutical innovations (cell, gene, RNA, and microbiome therapies), reproductive medicine, drug development, and industrial applications including enhanced fermentation processes and biopolymer production (McKinsey Global Institute, 2020). Industries are actively exploring new manufacturing options and selecting the right clones for producing biological alternatives to conventional products.

Figure 1: Examples of Biomanufacturing Systems



Explore in this article the critical stages and innovative technologies in upstream biomanufacturing development, focusing on organism selection, genetic modification, and process optimization, all supported by advanced automation and data management solutions. Examine how laboratory automation solutions can efficiently respond to time constraints and help researchers and industry achieve net zero scope. Walk through the biofoundry world and witness real-time application of functionalities, as demonstrated by Lesaffre Biofoundry at the end.

02 Upstream Development

This is the end of the preview. If you would like to download the entire casebook, please visit becls.co/43YM9Se



All products referenced are For Research Use Only. Not for use in diagnostic procedures.

© 2025 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. ECHO is a trademark or registered trademark of Labcyte Inc. in the United States and other countries. Labcyte is a Beckman Coulter company. All other trademarks are the property of their respective owners.

For Beckman Coulter's worldwide office locations and phone numbers, please visit Contact Us at beckman.com
2025-GBL-EN-107141-V1

